NCT02445976 2019-02-01Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.Innocrin PharmaceuticalPhase 2 Completed197 enrolled
NCT02130700 2018-05-07Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast CancerInnocrin PharmaceuticalPhase 2 Completed17 enrolled